Fibroproliferative and cardiometabolic disorders are estimated to contribute to 45% of deaths in the United States*.

As the magnitude of this unmet clinical need is resulting in intense efforts to develop novel therapeutics, opportunities to target fibrosis, obesity, type 2 diabetes, and cardiovascular disorders through the lens of a holistic approach to metabolic syndrome are exploding.

The Respiratory, CVRM & Liver Series is aimed to enable drug developers to eradicate these diseases and provide a better standard of care for patients.